Synaptogenix (SNPX) Competitors $2.12 -0.12 (-5.16%) Closing price 04/17/2025 03:50 PM EasternExtended Trading$2.10 -0.02 (-0.90%) As of 04/17/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. MRKR, SYBX, ORGS, QNTM, TXMD, MBRX, GOVX, ABVC, PHIO, and AFMDShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Marker Therapeutics (MRKR), Synlogic (SYBX), Orgenesis (ORGS), Quantum Biopharma (QNTM), TherapeuticsMD (TXMD), Moleculin Biotech (MBRX), GeoVax Labs (GOVX), ABVC BioPharma (ABVC), Phio Pharmaceuticals (PHIO), and Affimed (AFMD). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Marker Therapeutics Synlogic Orgenesis Quantum Biopharma TherapeuticsMD Moleculin Biotech GeoVax Labs ABVC BioPharma Phio Pharmaceuticals Affimed Marker Therapeutics (NASDAQ:MRKR) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends. Does the MarketBeat Community prefer MRKR or SNPX? Marker Therapeutics received 73 more outperform votes than Synaptogenix when rated by MarketBeat users. However, 66.67% of users gave Synaptogenix an outperform vote while only 64.66% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7564.66% Underperform Votes4135.34% SynaptogenixOutperform Votes266.67% Underperform Votes133.33% Do analysts prefer MRKR or SNPX? Marker Therapeutics currently has a consensus price target of $13.17, suggesting a potential upside of 1,044.93%. Synaptogenix has a consensus price target of $14.00, suggesting a potential upside of 561.94%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MRKR or SNPX more profitable? Synaptogenix has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Synaptogenix's return on equity of -42.14% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% Synaptogenix N/A -42.14%-29.42% Which has more volatility and risk, MRKR or SNPX? Marker Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Does the media prefer MRKR or SNPX? In the previous week, Synaptogenix had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Marker Therapeutics. Synaptogenix's average media sentiment score of 1.00 beat Marker Therapeutics' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the news media. Company Overall Sentiment Marker Therapeutics Neutral Synaptogenix Positive Do institutionals and insiders hold more shares of MRKR or SNPX? 22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 14.5% of Marker Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, MRKR or SNPX? Synaptogenix has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$6.59M1.87-$8.24M-$1.20-0.96SynaptogenixN/AN/A-$6.04M-$10.53-0.20 SummaryMarker Therapeutics beats Synaptogenix on 10 of the 18 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.94M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.206.8921.8217.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.085.936.443.98Net Income-$6.04M$142.99M$3.21B$247.73M7 Day Performance-7.24%4.43%2.87%1.81%1 Month Performance-26.05%-12.72%-8.64%-6.96%1 Year Performance-54.61%-9.42%11.47%1.30% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix2.6898 of 5 stars$2.12-5.2%$14.00+561.9%-55.9%$2.94MN/A-0.204Short Interest ↓Positive NewsGap DownMRKRMarker Therapeutics3.274 of 5 stars$1.17+6.4%$13.17+1,025.4%-73.3%$12.53M$6.59M-0.9860News CoveragePositive NewsSYBXSynlogicN/A$1.05-5.0%N/A-40.1%$12.22M$8,000.00-0.2580ORGSOrgenesisN/A$2.53+1.2%N/AN/A$12.14M$662,000.000.00150Upcoming EarningsGap DownQNTMQuantum BiopharmaN/A$6.30-6.3%N/AN/A$12.09MN/A-0.41N/AGap DownTXMDTherapeuticsMD1.1976 of 5 stars$1.04+1.0%N/A-46.6%$12.04M$1.76M0.00420Analyst ForecastMBRXMoleculin Biotech1.9552 of 5 stars$0.85+2.4%$6.00+606.7%-79.6%$11.89MN/A0.0020Short Interest ↑Gap DownGOVXGeoVax Labs2.3206 of 5 stars$0.85-20.5%$12.90+1,416.6%-43.2%$11.77M$3.95M-0.1510Analyst ForecastShort Interest ↑Analyst RevisionHigh Trading VolumeABVCABVC BioPharma0.8504 of 5 stars$0.90-2.7%N/A-16.2%$11.62M$509,788.00-1.0430Earnings ReportPHIOPhio Pharmaceuticals2.5843 of 5 stars$2.43+10.5%$4.00+64.6%-52.7%$11.61MN/A-0.2210AFMDAffimed3.5306 of 5 stars$0.72-8.8%$13.50+1,772.4%-86.0%$11.61M$877,000.000.00200Analyst ForecastGap Up Related Companies and Tools Related Companies Marker Therapeutics Alternatives Synlogic Alternatives Orgenesis Alternatives Quantum Biopharma Alternatives TherapeuticsMD Alternatives Moleculin Biotech Alternatives GeoVax Labs Alternatives ABVC BioPharma Alternatives Phio Pharmaceuticals Alternatives Affimed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNPX Stock Free SNPX Stock Alerts